Remission Induction, Maintenance, and Endoscopic Outcome with Oral 5-Aminosalicylic Acid in Intestinal Behçet’s Disease.

Remission Induction, Maintenance, and Endoscopic Outcome with Oral 5-Aminosalicylic Acid in Intestinal Behçet’s Disease. J Gastroenterol Hepatol. 2019 Apr 24;: Authors: Kinoshita H, Nishioka H, Ikeda A, Ikoma K, Sameshima Y, Ohi H, Tatsuno M, Kouyama J, Kawamoto C, Mitsui T, Tamura Y, Hashimoto Y, Nishio M, Ogashiwa T, Saigusa Y, Maeda S, Kimura H, Kunisaki R, Koike K Abstract BACKGROUND AND AIM: Oral 5-aminosalicylic acid (5-ASA) is recommended for the therapy of mild to moderate intestinal Behçet’s disease (BD). However, the induction remission efficacy and endoscopic outcomes of 5-ASA…

Read More

Mucosal 5-aminosalicylic acid concentration, drug formulation and mucosal microbiome in patients with quiescent ulcerative colitis.

Related Articles Mucosal 5-aminosalicylic acid concentration, drug formulation and mucosal microbiome in patients with quiescent ulcerative colitis. Aliment Pharmacol Ther. 2019 Mar 20;: Authors: Olaisen M, Spigset O, Flatberg A, Granlund AVB, Brede WR, Albrektsen G, Røyset ES, Gilde B, Sandvik AK, Martinsen TC, Fossmark R Abstract BACKGROUND: 5-aminosalicylic acid (5-ASA) is the first-line therapy for ulcerative colitis (UC). 5-ASA acts locally in the colonic mucosa by numerous proposed mechanisms, and is metabolised by N-acetyltransferase (NAT). Large variations in mucosal 5-ASA concentrations have been reported, but the underlying mechanisms are…

Read More

Systematic review with meta-analysis: high prevalence and cost of continued aminosalicylate use in patients with ulcerative colitis escalated to immunosuppressive and biological therapies.

Related Articles Systematic review with meta-analysis: high prevalence and cost of continued aminosalicylate use in patients with ulcerative colitis escalated to immunosuppressive and biological therapies. Aliment Pharmacol Ther. 2018 Dec 19;: Authors: Ma C, Guizzetti L, Cipriano LE, Parker CE, Nguyen TM, Gregor JC, Chande N, Feagan BG, Jairath V Abstract BACKGROUND: Aminosalicylates are the most frequently prescribed treatment for ulcerative colitis (UC). In the absence of empirical evidence, clinicians are uncertain whether to continue aminosalicylates in patients with UC after escalating therapy. AIMS: To quantify concomitant aminosalicylate use in…

Read More

Effect of Long-Term Mesalamine Therapy on Cancer-Associated Gene Expression in Colonic Mucosa of Patients with Ulcerative Colitis.

Related Articles Effect of Long-Term Mesalamine Therapy on Cancer-Associated Gene Expression in Colonic Mucosa of Patients with Ulcerative Colitis. Dig Dis Sci. 2018 Nov 26;: Authors: Bajpai M, Seril DN, Van Gurp J, Geng X, Alvarez J, Minacapelli CD, Gorin S, Das KK, Poplin E, Cheng J, Amenta PS, Das KM Abstract BACKGROUND: The role of 5-aminosalicylic acid (5-ASA or mesalamine) in the prevention of colorectal cancer in ulcerative colitis (UC) patients was reported, but the effect on molecular targets in UC colon mucosa is unknown. AIM: This observational study…

Read More

Concomitant Use of Aminosalicylates Is Not Associated with Improved Outcomes in Patients with Ulcerative Colitis Escalated to Vedolizumab.

Related Articles Concomitant Use of Aminosalicylates Is Not Associated with Improved Outcomes in Patients with Ulcerative Colitis Escalated to Vedolizumab. Clin Gastroenterol Hepatol. 2018 Dec 07;: Authors: Ma C, Kotze PG, Almutairdi A, Jairath V, Panaccione R PMID: 30528845 [PubMed – as supplied by publisher] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/30528845?dopt=Abstract

Read More

Stopping 5-aminosalicylates in patients with ulcerative colitis starting biologic therapy does not increase the risk of adverse clinical outcomes: analysis of two nationwide population-based cohorts.

Related Articles Stopping 5-aminosalicylates in patients with ulcerative colitis starting biologic therapy does not increase the risk of adverse clinical outcomes: analysis of two nationwide population-based cohorts. Gut. 2018 Nov 12;: Authors: Ungaro RC, Limketkai BN, Jensen CB, Allin KH, Agrawal M, Ullman T, Colombel JF, Jess T Abstract OBJECTIVE: The benefit of continuing 5-aminosalicylate (5-ASA) in patients with ulcerative colitis (UC) who initiate anti-tumour necrosis factor-alpha (anti-TNF) biologics is unknown. We aimed to compare clinical outcomes in patients with UC already on 5-ASA who started anti-TNF and then either…

Read More

miR-206 as a Biomarker for Response to Mesalamine Treatment in Ulcerative Colitis.

miR-206 as a Biomarker for Response to Mesalamine Treatment in Ulcerative Colitis. Inflamm Bowel Dis. 2018 Sep 11;: Authors: Minacapelli CD, Bajpai M, Geng X, Van Gurp J, Poplin E, Amenta PS, Brant SR, Das KM Abstract Background: MicroRNAs (miRNAs) are important post-translational regulators. Elevated levels of miR-206 in ulcerative colitis (UC) were associated with suppression of anti-inflammatory A3 adenosine receptor (A3AR) expression. However, the relationship of miR-206 to histologic remission in UC patients remains unknown. This study correlates expression levels of miR-206 with histologic remission in patients treated via…

Read More
<< Go Back